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Abstract 
A synthetic version of the human D4 (hD4) dopamine receptor was prepared. The G/C content of the natural gene was reduced by 14% without 
altering the amino acid composition of the corresponding protein sequence. HEK293 cells were transfected with the synthetic hD4 gene and stable 
clones resistant o G418 selected. The hD4 receptor expressed from the synthetic gene had identical pharmacological characteristics to the native 
hD4 receptor [(1991) Nature 350, 610-619; (1992) Nature 358, 149-1521. Functional studies with cells expressing the synthetic hD4 gene indicated 
negative coupling of this receptor to adenylate cyclase. 
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1. Introduction 
Dopamine receptors are the sites of action of many of 
the anti-psychotic drugs currently used in the treatment 
of schizophrenia. Recent advances in molecular biology 
have dramatically expanded the number of known 
dopamine receptors. It is now clear that there are two 
families of receptors, the ‘D,-like’ (Di and DS) and the 
‘D,-like’ (Dz, D3 and D4) [3]. 
The human D4 (hD4) dopamine receptor was cloned 
initially as a hybrid of genomic DNA and cDNA. This 
clone has been shown, by transient expression in COS-7 
cells, to have a high affinity for the atypical neuroleptic, 
clozapine [l]. Variants of the hD4 receptor, containing 
a variable number of 48 bp imperfect repeat units in 
intracellular loop three, were later reported [3-51. Ex- 
pression of the hybrid hD4.2 (hD4 receptor with two 
repeat units) receptor clone was reported in baculovirus 
[6]. Expression was achieved by deleting the first two 
introns of the D4 genomi=DNA hybrid and replacing 
them with a synthetic oligonucleotide with a reduced 
G/C content. 
The most common form of the hD4 receptor in human 
populations is D4.4 [5]. Stable expression of a function- 
ally coupled hD4.4 receptor in a human cell line is there- 
fore important for drug discovery. The hD4 gene has an 
unusually rich G/C content, and dit%culties have been 
found in attempting stable expression of this receptor [7]. 
We decided to produce a synthetic version of the gene 
with an overall reduction in G/C content. The synthetic 
hD4.4 gene was transfected into HER293 (human em- 
bryonic kidney) cells for stable expression. Functional 
expression of other G-protein coupled receptors, includ- 
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ing the human dopamine D, receptor, has been demon- 
strated in this cell line [8-lo]. The transfected HER293 
cells expressed high levels of a receptor with pharmacol- 
ogy similar to that described for the hD4.2 isoform 
[1,2,6]. The receptor expressed from the synthetic gene 
was also shown, in functional assays, to be negatively 
coupled to adenylate cyclase. 
2. Materials and methods 
2.1. Production of a synthetic hD4 gene 
A modified version of the human D4.4 receptor was constructed by 
British Biotechnology Plc. Ltd. UK. the G/C content of the synthetic 
hD4 was reduced to 60%. Suitable restriction sites (EcoRl and HindIII) 
were added to allow subcloning into an expression vector. Unique Pstl 
and BamHl restriction sites were engineered into the construct. This 
allowed the insertion of differing numbers of 48 bp imperfect repeats 
into intracellular loop III. 
2.2. Construction of an expression vector for the hD4.4 gene 
The synthetic hD4.4 cDNA was isolated as an gcoRl-HinIII frag- 
ment by the GeneClean procedure (BiolOl). The puri8ed hD4.4 frag- 
ment was ligated into the corresponding sites in the mammalian expres- 
sion vector, pCDN, using the Amersham ligation system. The ligated 
DNA was transformed into Escherichia coli Sure cells (Stratagene) and 
colonies were selected by ampicillin resistance. Colonies containing the 
hD4.4 were selected by PCR screening with primers specific for the 
pCDN polylinker, using Cetus Amplitaq. The DNA sequence of the 
hD4.4 cDNA was confirmed across the cloning sites in pCDN. One 
construct, pCDNHD4.4, was chosen to transfect into mammalian cells. 
Transfecting DNA was purified by Magic maxi columns (Promega). All 
procedures were done using standard methodologies [l11. 
2.3. Transfections into COS-I cells (transient) and HEK293 cells 
(stable) 
For transient ransfections 1.5 x lo6 COS-1 cells were seeded in 75 
cm* flasks (Costar) in MEM medium (containing Earl’s salts and 
rghuamine; Gibco) supplemented with 10% FCS (G&co) and 1% 
r&namine (G&o). Cells were incubated at 5% CO*, 37°C overnight. 
Each flask of COS-1 cells was transfected with 2Opg of DNA using the 
DEAE dextran methodology [12]. Cells were scraped 48 h post-trans- 
fection. The human Dz dopamine receptor (hD2) cDNA was trans- 
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fected as the positive control. This receptor was obtained from the 
University of Oregon. 
For stable transfections 2x lo6 HEK293 cells were seeded in 100 mm 
petri-dishes (Costar) in MEM medium supplemented with 10% FCS 
(G&co) at 5% COr, 37°C overnight. Each Petri-dish of cells was trans- 
fected with 20 pug DNA using the calcium phosphate protocol [13]. 
During transfection cells were incubated at 3% CO2 overnight. Selec- 
tion medium containing 800 &ml G418 (Gibco; geneticin) was added 
48 h post-transfection. After 15 days G418-resistant clones were se- 
lected by ring cloning and expanded for further analysis. 
2.4. Preparation of membranes and radioligand binding studies 
Colony selection was carried out using in situ binding. Cells were 
grown to contluence in 6-well plates. The medium was removed and the 
cells were washed with 1 ml assay buffer (50 mM Tris containing 120 
mM NaCl, 5 mM KCl, 5 mM MgCl,, 1.5 mM CaCl,, pH 7.4, at 22°C). 
Cells were then incubated with approximately 1.5 nM [Hjspiperone in 
a 6nal volume of 1 ml assay buffer containing 0.35% BSA for 2 h at 
22°C. At the end of the incubation, separation of bound and free ligand 
was achieved by inversion of the plates and rapid washing of each well 
with 4 x 5 ml ice-cold assay buffer. Radioligand remaining bound to 
cells was removed with 10% SDS and radioactivity counted in the 
normal manner. Membranes for radioligand binding studies were pre- 
pared from frozen pellets of hD4.4 cells and radioligand binding carried 
out as described earlier [14]. The concentration of [3Hjspiperone used 
was 0.4-0.6 nM. 
2.5. Functional studies 
HEK293 cells expressing the hD4.4 receptor were removed from 
confluent 75 cm* flasks by replacing the medium with phosphate- 
buffered saline, and harvested by centrifugation. Cells (2 x 10’) were 
pre-incubated (15 min) with isobutyhnethylxanthine (5OOpM) in Ultra- 
CHO (BioWhittaker). Samples were then incubated with the agonist 
and/or antagonist for 10 min at 37°C before the addition of forskolin 
(20 PM; Sigma). The final volume was 0.5 ml. After a further 10 min 
at 37’C the reaction was terminated by the addition of 3 M perchloric 
acid. Cyclic AMP was extracted into the aqueous phase of a 50 : 50 
mixture of trioctylamine : trichlorotritluoroethane and measured by 
CAMP radioimmunoassay @‘EN DuPont). 
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Fig. 1. Wilbur-Lipman DNA alignment of the synthetic and native D4.4 genes. Matching residues are marked. Both genes are 86% identical and 
differ in their respective G/C contents by 14% without altering the amino acid sequence. 
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3. Results and discussion 
In order 
B_ were determined in satura- 
tion experiments. One of the clones, expressing 2 pmol/ 
mg protein, was selected for radioligand binding and 
functional studies. 
Radioligand binding studies were carried out under 
the same conditions as we have used previously for hD2 
and hD3 receptors cloned in CHO cells [14]. These con- 
ditions are different to those employed by others in pre- 
vious hD4.2 studies [1,2,6,16]. However, neither the 
change in assay buffer nor the change in temperature had 
20 
149 
Fig. 2. Plasmid pCDNHD4.4 including the synthetic hD4.4 gene. The 
position of the hD4.4,48 bp repeat cassette is marked by an arrow. 
any effect on radioligand binding (data not shown). Fig. 
3 shows the results of [3H]spiperone binding studies with 
membranes obtained from hD4.4/293 cells. Data was 
analysed according to a single site fit [15], using the Kd 
for [3H]spiperone obtained in the saturation studies (0.14 
nM). 
The Ki’S obtained are shown in Table 1. Dopamine, 
spiperone and clozapine showed atlinities at the hD4.4 
receptor expressed in HER293 clones consistent with the 
values obtained by others in different cell lines [ 1,2,6,16]. 
The binding characteristics of the product of our syn- 
thetic gene are therefore similar to those described by 
others for this receptor. 
Stimulation by forskolin (20 PM) produced a 25-fold 
stimulation of cellular CAMP over basal levels (approxi- 
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Fig. 3. Inhibition of [WJspiperone (0.40.6 nM) binding by spiperone (o), clozapine (0) or dopamine (0). Each point is the mean of 6 separate 
experiments. 
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Fig. 4. Inhibition of forskolin (20 PM)-induced stimulation of adenylyl cyclase by quinpirole in the absence (0) or presence (0) of 1 nM spiperone. 
Each point is the mean f S.E.M. of five experiments assayed in triplicate. 
mately 2 pmoYl0’ cells), as measured by CAMP radioim- 
munoassay. Forskolin-stimulated CAMP was inhibited 
by the dopamine receptor agonist, quinpirole, in a con- 
centration-related manner (Fig. 4), producing > 60% in- 
hibition at 10 ,uM. The quinpirole inhibition curve was 
shifted to the right by spiperone (1 nM), which did not 
itself have any effect on CAMP levels. These results sug- 
gest that the hD4.4 receptor is negatively coupled to 
adenylate cyclase in these cells, similar to the effect re- 
ported in mouse retinas [17]. However, to the best of our 
knowledge, this is the first report of the hD4.4 receptor 
coupling in a human cell line. 
In conclusion, HEK 293, a human kidney cell line, 
expressing high levels of hD4.4 receptor, was obtained. 
Negative coupling to adenylate cyclase was demon- 
strated in this system. The stable expression of the hD4.4 
receptor in a human cell line will aid our understanding 
of the biochemistry and pharmacology of this receptor. 
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Table 1 
Affinities of dopamine, spiperone and clozapine for human D4.4 recep- 
tor expressed in HEK293 cells: comparison with literature data 
Dws HEK293 Van To1 et al. Mills et al. Lahti et al. 
[1,21 (CW I61 (SW 1131 (CW 
Dopamine 394 f 76.1 450,- - - 
Spiperone 0.188 + 0.016 0.08,O.lO 0.3 - 
Clozapine 29.6 f 1.84 9,25 53 29 
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